Heart failure & cardiomyopathiesCohort study
Endomyocardial biopsy: safety and prognostic utility in paediatric and adult myocarditis in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Long-Term Registry
- Prospective registry study
- multicentre
- ESC EURObservational Research Programme registry
Authors' conclusion
Endomyocardial biopsy was safe, and cardiac magnetic resonance using Lake Louise criteria was less sensitive, particularly in children. Virus-negative lymphocytic myocarditis was predominant both in children and adults, and use of immunosuppressive treatments was low. Lower left ventricular ejection fraction and the need for immunosuppressants at diagnosis were independent predictors of unfavourable outcome events at 1 year.
Study context
- Population
- Adults and children with clinically suspected or biopsy-proven myocarditis (2013 ESC criteria), ESC Cardiomyopathy and Myocarditis Long-Term Registry493 adults · 88 children
- Participants
- 581 participants
- Exposure
- Children vs adults; clinically suspected vs biopsy-proven myocarditis
- Group 1n = 233
- Group 2n = 222
- Group 3n = 126
- Outcome
- Outcome events: death/heart transplantation, VAD or ICD implantation, hospitalization for cardiac causes
- Follow-up
- 1 year
Main finding
As reported in the abstract
Died
11/410 (2.7%)
Heart transplant
7 (1.7%)
Ventricular assist device (VAD)
3 (0.7%)
Implantable cardioverter defibrillator (ICD) implantation
16 (3.9%)
Observational data: associations, not effects.
Further findings
Classical myocarditis pattern on CMR, biopsy-proven myocarditis
P < 0.001
Safety
Endomyocardial biopsy complications
P = NS
Endomyocardial biopsy complications
- No procedure-related death
Original publication
Summarised from the published abstract; every number is checked against it